Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02744092 · ClinicalTrials.gov registry record · NA

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

A NA study of Cancer and Venous Thromboembolism, sponsored by Alliance Foundation Trials.

Completed
Registry status
NA
Development phase
811
Enrollment target
20
Study locations

NCT02744092 is a NA study of Cancer and Venous Thromboembolism that has completed, run by Alliance Foundation Trials. The registered enrollment target is 811 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02744092, a NA study of Cancer and Venous Thromboembolism, has completed, sponsored by Alliance Foundation Trials.

COMPLETED
Registry status
NA
Development phase
811 participants
Enrollment target
20
Study locations

Study Summary

The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The comparator is low molecular weight heparin (LMWH) alone or with warfarin. The information gained will empower cancer patients and physicians to make more informed choices about anticoagulation strategies to manage VTE.

Conditions Studied

Cancer Venous Thromboembolism Deep Vein Thrombosis (DVT) Pulmonary Embolism (PE) Blood Clot

Interventions

  • DRUG Apixaban
  • DRUG Warfarin
  • DRUG Rivaroxaban
  • DRUG Edoxaban
  • DRUG Dabigatran

Study Locations (20)

California

  • South County Hematology - Chula Vista
  • Sharp Rees-Stealy - Chula Vista
  • Washington Hospital Healthcare System - Fremont
  • Washington Hospital - Fremont
  • VA Central California Fresno Medical Center - Fresno
  • Cancer Center Oncology Medical Group - La Mesa
  • Medical Oncology Associates- San Diego - San Diego
  • Sharp Memorial Hospital - San Diego
  • Sharp Rees-Stealy - San Diego
  • UCSF Medical Center - Mission Bay - San Francisco
  • Saint Joseph's Medical Center - Stockton

Florida

  • Morton Plant Hospital - Clearwater
  • Breast Cancer Center at Memorial Regional Hospital - Hollywood
  • Memorial Cancer Institute at Memorial Regional Hospital - Hollywood
  • Memorial Regional Hospital - Hollywood
  • Hollis Cancer Center - Lakeland
  • Breast Cancer Center at Memorial Hospital West - Pembroke Pines
  • Memorial Cancer Institute at Memorial Hospital West - Pembroke Pines

Connecticut

  • Middlesex Hospital - Middletown
  • The Stamford Hospital - Stamford

Trial Details

FieldValue
Enrollment Target 811 participants
Start Date 2016-12-13
Est. Completion 2021-02-22
Phase NA

Sponsor

Alliance Foundation Trials

20 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02744092

The ClinicalTrials.gov registry entry for NCT02744092 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 811 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (77% lower). The listed sponsor is Alliance Foundation Trials, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Apixaban is the first listed.

NCT02744092 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Connecticut.

Frequently Asked Questions

What is clinical trial NCT02744092 about?

NCT02744092 is a clinical study titled "Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer". The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The compara...

What is the current status of trial NCT02744092?

This trial is currently completed. It is a NA study. The enrollment target is 811 participants. The study started on 2016-12-13. Estimated completion is 2021-02-22.

What conditions does trial NCT02744092 study?

This clinical trial studies the following conditions: Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot.

What interventions are being tested in trial NCT02744092?

The interventions under investigation include: Apixaban (DRUG), Warfarin (DRUG), Rivaroxaban (DRUG), Edoxaban (DRUG), Dabigatran (DRUG).

Who is sponsoring clinical trial NCT02744092?

This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02744092 being conducted?

This trial has 20 study locations across California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Venous Thromboembolism

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.